Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.…
Vir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock Sale
Vir Biotechnology (NASDAQ: VIR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 367 employees.
The shares were at 8.390 USD on 20 November 2026, up 63.9% over 52 weeks. Its 52-week range is 4.815 USD to 14.38 USD: the price is 41.7% below the high and 74.2% above the low.
Its market capitalisation is 1.56B USD.
Vir Biotechnology reports return on equity of -57.2% and an operating margin of -70.2%.
It holds more cash than debt, a net cash position of 367.58M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 23.13 USD is 175.6% above the current price. The next earnings report is expected on 24 February 2027.